Hyperfine posts $6m quarterly sales on 14 portable MRI units, holds full-year outlook

Hyperfine (Nasdaq: HYPR) booked $6.0m of revenue in the third quarter of 2026, 73% more than a year earlier, after selling 14 of its Swoop portable brain MRI systems. The company reported the results on 9 November and recorded a net loss of $6.0m for the period.

Management left its full-year revenue guidance at $20m-$22m. The company did not provide, in the material available, a year-to-date revenue figure, so how much of that target has been delivered cannot be calculated from the information on file.

On the product side, Hyperfine's latest Optive AI software has received FDA clearance and CE and UKCA marking, and the company has launched its Model 2 scanner in Europe and the UK. Pricing and early order data for Model 2 were not disclosed.

Hyperfine has also finished enrolling patients in its Contrast PMR study and expects to file with the FDA by the end of 2026. The regulatory pathway and the intended indication were not specified, and no other study details were available.

Separately, the company intends to file a new $150m shelf registration to succeed the current one, which lapses in November 2026. By way of context, a shelf registration lets a listed company register securities in advance so it can sell them later; the filing does not mean any offering has been launched, and Hyperfine did not say how it might use the capacity.